SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales
Biotech firm Swedish Orphan Biovitrum (SOBI: SS), has announced total revenues of 665.9 million Swedish kronor ($99.8 million) for the third quarter of 2014, an increase of 25.2% on figures from the same period last year.
Orfadin doubles its sales
Product revenues stood at 532.3 million kronor, up from 393.5 million kronor in the same period last year, and SOBI reports revenues for Key Therapeutic Areas as 372 million kronor – an increase of 51%. Orfadin (nitisinone) had a 100% boost in sales, from 81.9 million kronor in the third quarter of 2013 to 163.5 million kronor this quarter. It cites the beginning of direct sales in North America in the second quarter as the reason for such a big leap in revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze